Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2025-10-07 eCollection Date: 2025-01-01 DOI:10.5334/gh.1460

Jagat Narula, Javed Butler, Yazied Chothia, Debasish Bannerjee, Faical Jarraya, Ifeoma Ulasi, Valerie Luyckx

{"title":"Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.","authors":"Jagat Narula, Javed Butler, Yazied Chothia, Debasish Bannerjee, Faical Jarraya, Ifeoma Ulasi, Valerie Luyckx","doi":"10.5334/gh.1460","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical impact of diabetes medications including sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on cardiovascular (CV) and kidney disease outcomes has focused attention on the inter-relatedness of kidney and heart health, both within and outside the context of diabetes. These conditions often co-exist in one individual resulting in frequent hospitalisations and premature deaths. Herein, we provide an updated comprehensive state-of-the-art review, summarising the linkages between heart disease and kidney disease, the mechanisms connecting these conditions, common risk factors, management, implications for health systems, and the impact on patients, particularly in low-resource settings. As experts representing the World Heart Federation (WHF) and International Society of Nephrology (ISN), we highlight areas of opportunity and provide recommendations on improving access to care for the growing numbers of patients with heart and kidney diseases with a focus on low-income and middle-income countries (LMICs).</p>","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"88"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513359/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1460","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The clinical impact of diabetes medications including sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on cardiovascular (CV) and kidney disease outcomes has focused attention on the inter-relatedness of kidney and heart health, both within and outside the context of diabetes. These conditions often co-exist in one individual resulting in frequent hospitalisations and premature deaths. Herein, we provide an updated comprehensive state-of-the-art review, summarising the linkages between heart disease and kidney disease, the mechanisms connecting these conditions, common risk factors, management, implications for health systems, and the impact on patients, particularly in low-resource settings. As experts representing the World Heart Federation (WHF) and International Society of Nephrology (ISN), we highlight areas of opportunity and provide recommendations on improving access to care for the growing numbers of patients with heart and kidney diseases with a focus on low-income and middle-income countries (LMICs).

查看原文本刊更多论文

优化心脏和肾脏疾病患者的护理途径：世界心脏联合会和国际肾脏病学会白皮书。

包括钠-葡萄糖共转运体-2 （SGLT2）抑制剂、非甾体矿皮质激素受体拮抗剂（MRAs）和胰高血糖素样肽1受体激动剂（GLP-1 RAs）在内的糖尿病药物对心血管（CV）和肾脏疾病结局的临床影响，已将注意力集中在糖尿病内外肾脏和心脏健康的相互关系上。这些情况往往同时存在于一个人身上，导致频繁住院和过早死亡。在此，我们提供了一份最新的综合综述，总结了心脏病和肾脏疾病之间的联系，这些疾病之间的联系机制，常见的危险因素，管理，对卫生系统的影响，以及对患者的影响，特别是在资源匮乏的环境中。作为代表世界心脏联合会（WHF）和国际肾脏病学会（ISN）的专家，我们强调了机会领域，并就改善日益增多的心脏和肾脏疾病患者获得护理的机会提出建议，重点是低收入和中等收入国家（LMICs）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.